Salarius Pharmaceuticals LLC

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Houston, Texas. The company employs 8 people and reports revenue exceeding $10,000. Salarius focuses on developing innovative cancer therapies for patients lacking effective treatment options. Salarius' product portfolio centers around seclidemstat, a reversible LSD1 inhibitor, and SP-3164, an oral small molecule targeted protein degrader. Seclidemstat is currently undergoing a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and related sarcomas. This promising drug has received several designations from the U.S. Food and Drug Administration, including Fast Track, Orphan Drug, and Rare Pediatric Disease designations for Ewing sarcoma. Additionally, Salarius is investigating the potential of seclidemstat in other cancers with significant unmet medical needs, with a second Phase 1/2 clinical study underway at MD Anderson Cancer Center for hematologic cancers. Salarius Pharmaceuticals has garnered financial support from organizations like the National Pediatric Cancer Foundation and the Cancer Prevention and Research Institute of Texas (CPRIT) to advance its Ewing sarcoma clinical program. For more information about Salarius Pharmaceuticals' groundbreaking cancer research and treatments, please visit their website at salariuspharma.com. You can also stay updated on their latest advancements by following them on Twitter and LinkedIn.